MAPK8 and neoplasm: WB analysis demonstrated that Ro 48-8071 reduced JNK phosphorylation, and co-treatment with the JNK inhibitor SP600125 further enhanced the anti-tumor effects of Ro 48-8071 in vivo (Figs. 6E, F, G–I and S5).